Kelly Stratton, MD
Kelly L. Stratton, M.D., is an Associate Professor of Urologic Oncology at the University of Oklahoma Stephenson Cancer Center. Prior to joining the OU Department of Urology in 2014, he completed his fellowship training in the Department of Surgery (Urology Service) at Memorial Sloan-Kettering Cancer Center in New York, and his residency at Vanderbilt University Medical Center Department of Urology. He completed his M.D. with special distinction at the University of Oklahoma College of Medicine in 2007.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Sanofi Genzyme Corp.Date added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (General Urology)Ineligible company:Bayer CorporationDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (General Urology)Ineligible company:MJH Life SciencesDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:OakstoneDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:AstraZenecaDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:Janssen PharmaceuticalsDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:MJH Life SciencesDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:EbixDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Specialty Not Specified)Ineligible company:Myovant SciencesDate added:Date updated:01/19/2024
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Specialty Not Specified)Ineligible company:Roche/GenentechDate added:Date updated:01/19/2024